Wall Street analysts expect that Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) will report ($0.66) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Trillium Therapeutics’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.78). Trillium Therapeutics reported earnings per share of ($0.72) in the same quarter last year, which suggests a positive year-over-year growth rate of 8.3%. The company is scheduled to announce its next earnings results on Friday, March 8th.
On average, analysts expect that Trillium Therapeutics will report full year earnings of ($2.47) per share for the current fiscal year, with EPS estimates ranging from ($2.52) to ($2.42). For the next year, analysts forecast that the firm will report earnings of ($2.04) per share, with EPS estimates ranging from ($2.43) to ($1.34). Zacks’ EPS calculations are an average based on a survey of research analysts that that provide coverage for Trillium Therapeutics.
Several analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Trillium Therapeutics in a research report on Monday, August 13th. Zacks Investment Research raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Wealth Alliance Advisory Group LLC purchased a new position in shares of Trillium Therapeutics during the third quarter worth about $126,000. Stanley Laman Group Ltd. lifted its position in Trillium Therapeutics by 26.7% in the second quarter. Stanley Laman Group Ltd. now owns 137,091 shares of the biotechnology company’s stock valued at $823,000 after purchasing an additional 28,907 shares during the last quarter. Morgan Stanley lifted its position in Trillium Therapeutics by 25.2% in the third quarter. Morgan Stanley now owns 356,655 shares of the biotechnology company’s stock valued at $2,068,000 after purchasing an additional 71,860 shares during the last quarter. Renaissance Technologies LLC lifted its position in Trillium Therapeutics by 245.3% in the second quarter. Renaissance Technologies LLC now owns 144,000 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 102,300 shares during the last quarter. Finally, Baker BROS. Advisors LP lifted its position in Trillium Therapeutics by 25.0% in the second quarter. Baker BROS. Advisors LP now owns 511,763 shares of the biotechnology company’s stock valued at $3,071,000 after purchasing an additional 102,440 shares during the last quarter. 47.47% of the stock is owned by institutional investors.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Article: What is Liquidity?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.